Jazz Pharmaceuticals to acquire Actio Biosciences in deal worth over $1.3 billion

Jazz Pharmaceuticals announced an agreement to purchase Actio Biosciences, a San Diego biotech focused on genetic epilepsies.

The transaction could total just over $1.3 billion, with $820 million paid upfront and up to $500 million in milestone-based earn-outs tied to regulatory and sales targets.

Actio's lead program is a candidate for a rare KCNT1-related epilepsy, while another pipeline asset targeting Charcot-Marie-Tooth disease will be placed into a new spin‑out that Jazz will own a minority stake in.

The companies expect to close the acquisition in the last quarter of 2026, adding to a recent wave of private biotech buyouts.